ClinicalTrials.gg
Active, not recruitingNCT07377539Updated Oct 23, 2026

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of JZP047 in Healthy Participants

A Phase 1 interventional study of JZP047 and Placebo in Healthy Participants, sponsored by Jazz Pharmaceuticals. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Jazz Pharmaceuticals · Phase 1, Interventional, and Treatment

Updated Oct 23, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a Phase 1, double-blind, sponsor-unblinded, randomized, placebo-controlled study designed to characterize the safety, tolerability, and PK of JZP047 in healthy participants following single-ascending doses of study intervention. Additionally, the effect of food on PK following a single dose of JZP047 will be assessed through comparison of PK between the fed and fasted states.

Read the detailed description

The study will consist of 2 parts: a single-dose ascending part (Part A [SAD] and a single dose under fed conditions part (Part B [Fed PK]).

The study design for Part A will be double-blind, sponsor-unblinded, randomized, and placebo-controlled. Part B, the single dose under fed conditions, will have an open-label study design.

Part A will characterize safety, tolerability, and PK following single doses of JZP047 and matching placebo in healthy male and female participants. Part B will explore the effect of food on a single dose of JZP047 in healthy male and female participants in the fed state.

02

Conditions studied

  • Healthy Participants

Keywords

  • Healthy Participants
  • JZP047
03

In context

Lead sponsor

Jazz Pharmaceuticals is the lead sponsor of 173 studies on the registry; 18 are open to participants now.

Of its 42 completed or terminated interventional studies of FDA-regulated products, 32 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Participants are eligible to be included in the study only if all of the following criteria apply:

  1. Healthy participants 18 to 55 years of age, willing and able to comply with study requirements.
  2. Male participants are eligible to participate if they agree to the following during the study intervention period and for at least 120 days after the last dose of study intervention:

    • Refrain from donating sperm.
    • Use /barrier as follows:

      • Use a male condom with female partner and use of an additional highly effective contraceptive method with a failure rate of \< 1% per year and should also be advised of the benefit of a female partner using a highly effective method of contraception, as a condom may break or leak, when having sexual intercourse with a woman of (WOCBP) who is currently not pregnant.
      • Agree to use a male condom when engaging in any activity that allows for passage of ejaculate to another person.
  3. Female participants are eligible to participate if:

    • She is a woman of nonchildbearing potential (WONCBP).
    • Pregnancy testing will be performed prior to administration of study intervention to confirm female participants are not pregnant.

Participants are excluded from the study if any of the following criteria apply:

  1. History of or presence of medical illness or disorder or have a medical issue that may interfere with absorption, distribution, metabolism, or excretion of drugs..
  2. History or presence of clinically significant allergy (other than seasonal allergies that do not require treatment during the study) or clinically significant allergy to adhesive bandages, adhesive dressing, patches, or medical tape.
  3. History (within 5 past years) or presence of a diagnosis of alcohol abuse, a substance abuse disorder, known drug dependence, or seeking of treatment for an alcohol- or substance abuse-related disorder.
  4. Current diagnosis of or receiving treatment for depression; past (within 5 years) clinically significant major depressive episode.
  5. History of suicide attempt, current suicidal risk as determined from history, or presence of active suicidal ideation.
  6. Presence of any other condition that will cause a risk to participants if they participate in the study as determined by the investigator.
  7. Poor peripheral venous access or history of fainting (or passing out) during blood draws.
  8. Use or intent to use any prescription medications or nonprescription drugs (including vitamins, recreational drugs, and dietary or herbal supplements) within 14 days or for 5 half-lives, whichever is longer prior to Check-in and throughout the conduct of the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
86 participants (estimated)

Study arms

  • Experimental
    Part A: JZP047

    Healthy participants who are randomized to JZP047.

    Drug: JZP047

  • Placebo comparator
    Part A: Placebo

    Healthy participants who are randomized to placebo.

    Other: Placebo

  • Experimental
    Part B: JZP047

    Healthy participants who will receive JZP047.

    Drug: JZP047

Interventions

  • DrugJZP047

    Single dose

  • OtherPlacebo

    Single dose

06

What researchers measure

Primary outcomes

  1. Number of Participants Reporting Treatment-emergent Adverse Events (Part A)

    Time frame: Baseline up to Day 90

  2. Number of Participants Reporting Treatment-emergent Adverse Events (Part B)

    Time frame: Baseline up to Day 90

  3. Number of Participants Who Discontinued The Study (Part A)

    Time frame: Baseline up to Day 90

  4. Number of Participants Who Discontinued The Study (Part B)

    Time frame: Baseline up to Day 90

  5. Pharmacokinetic Parameter Maximum Concentration (Part A)

    Time frame: Up to 90 days

  6. Pharmacokinetic Parameter Time to Maximum Concentration and Time Before the Start of Absorption (Part A)

    Time frame: Up to 90 days

  7. Pharmacokinetic Parameter Terminal Elimination Half-life (Part A)

    Time frame: Up to 90 days

  8. Pharmacokinetic Parameter Terminal Elimination Rate Constant (Part A)

    Time frame: Up to 90 days

  9. Pharmacokinetic Parameter Volume of Distribution During Terminal Phase (Part A)

    Time frame: Up to 90 days

  10. Pharmacokinetic Parameter Oral Clearance (Part A)

    Time frame: Up to 90 days

  11. Pharmacokinetic Parameter Area Under the Concentration-Time Curve (Part A)

    Area under the concentration-time curve from time 0 to 24 (AUC0-24), 0 to last measurable concentration (AUClast), and 0 to infinity (AUC∞) will be assessed.

    Time frame: Up to 90 days

  12. Pharmacokinetic Parameter Percentage of The Area Under the Concentration-Time Curve From Time Infinity Due to Extrapolation From The Last Quantifiable Concentration to Time Infinity (Part A)

    Time frame: Up to 90 days

Secondary outcomes

  1. Dose Proportionality of JZP047 Cmax (Part A)

    Time frame: Up to 90 days

  2. Dose Proportionality of JZP047 AUC0-last and AUC∞

    Time frame: Up to 90 days

  3. The Effect of Food On The Single Dose PK of JZP047 Cmax

    Time frame: Up to 90 days

  4. The Effect of Food On The Single Dose PK of JZP047 AUC0-last and AUC∞

    Time frame: Up to 90 days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Feb 2026 (actual). Primary completion is estimated for Nov 2026, 9 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Jul 2026 → Nov 2026 and completion Jul 2026 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2026
First posted
Jan 30, 2026
StartActual
Feb 3, 2026
Primary completionEst.
Nov 30, 2026was Jul 2026
CompletionEst.
Nov 30, 2026was Jul 2026
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 23, 2026
Primary completion
Jul 5, 2026→Nov 30, 2026
Oct 23, 2026
Study completion
Jul 5, 2026→Nov 30, 2026
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Recruiting→Active, not recruiting
    Primary completion Jul 5, 2026→Nov 30, 2026
    Study completion Jul 5, 2026→Nov 30, 2026
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07377539
Collaborators
Jazz Pharmaceuticals Ireland Limited
Responsible party
Sponsor
First posted
Jan 30, 2026
Start date
Feb 3, 2026
Primary completion
Nov 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Oct 23, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion